STS/EACTS Latin America Cardiovascular Surgery Conference September 21-22, 2017 | Cartagena, Colombia

info@cardiovascularsurgeryconference.org www.CardiovascularSurgeryConference.org



Leonardo Salazar MD., MSc.
Director ECMO and VAD program FCV
Bucaramanga, Colombia







## Relevant Financial Relationship Disclosure Statement

The following relevant financial relationships exist related to my role in this session: Speaker St Jude Medical now Abbott

## ECMO as circulatory support is completely different than respiratory support

• FCV 2017 ELSO registry report

	ADULTS		
	Cannulated	Decannulation	Discharge
Respiratory	22	19(86%)	17(77%)
Cardiac	45	26(57.8%)	18(40%)

#### ECMO as MCS some facts

- high-risk, complex, and resource-intensive
- has grown rapidly
- Save some patients
- Outcomes are suboptimal in cardiac surgery

### Poscardiotomy Adults

```
Survival to discharge
Brasil a* 4/24(16%)
Brasil b* 1/9 (16%).
Colombia FCV 3/15 (20%)
Vasoplegia + poscardiotomy 0/6 (0%)
Poscardiotomy arrested 0/2 (0%)
```

### Primary Graft Dysfunction

```
Survival to discharge
     Brasil b* 8/11 (72%)
     Colombia FCV 4/7 (57%)
       Proactive 4/5 (80%)
       Reactive 0/2 (0%)
ECMO as MCS in cath lab
     Survival to discharge
     Colombia FCV 13/21 (61%)
          Proactive 8/8 (100%)
```

### ECMO as a Bridge to Transplant

Survival to discharge Brasil 3/9 (33%) -Caneo et al, Arq Bras Cardiol. 2014-

Colombia 5/9 (55%) –Salazar et al, Acta Colomb Cuid Intensivo 2015;15:178-86-

ECMO in a complex cardiac surgery + prolonged CBP + difficult CBP weaning + refractory high dose multiple inotropes/vasoconstrictors = BAD OUTCOME

# ECMO as proactive support in primary graft dysfunction and complex cath lab patients has good outcomes

ECMO is not the best MCS for bridging to transplant. Switching to temporary or long term VAD or using them from the beginning would be a better option